IN2015DN01093A - - Google Patents

Info

Publication number
IN2015DN01093A
IN2015DN01093A IN1093DEN2015A IN2015DN01093A IN 2015DN01093 A IN2015DN01093 A IN 2015DN01093A IN 1093DEN2015 A IN1093DEN2015 A IN 1093DEN2015A IN 2015DN01093 A IN2015DN01093 A IN 2015DN01093A
Authority
IN
India
Prior art keywords
mini
granule
mini tablets
composition
tablets
Prior art date
Application number
Inventor
Gabriel Marinus Henricus Meesters
Ferdinand Antoine Spros
Original Assignee
Dsm Sinochem Pharm Nl Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Sinochem Pharm Nl Bv filed Critical Dsm Sinochem Pharm Nl Bv
Publication of IN2015DN01093A publication Critical patent/IN2015DN01093A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

The present invention relates to a composition comprising a first granule with an antibiotic and a second granule with a ß-lactamase inhibitor wherein at least one of the granules is a mini tablet (a particle with defined dimensions) a composition contained in a sachet pharmaceutical compositions comprising mini tablets the use of mini tablets and a process for the preparation of mini tablets.
IN1093DEN2015 2012-08-28 2013-08-26 IN2015DN01093A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12182026 2012-08-28
PCT/EP2013/067599 WO2014033077A1 (en) 2012-08-28 2013-08-26 Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets

Publications (1)

Publication Number Publication Date
IN2015DN01093A true IN2015DN01093A (en) 2015-06-26

Family

ID=46963435

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1093DEN2015 IN2015DN01093A (en) 2012-08-28 2013-08-26

Country Status (5)

Country Link
US (1) US20150238425A1 (en)
EP (1) EP2890366A1 (en)
CN (1) CN104582692A (en)
IN (1) IN2015DN01093A (en)
WO (1) WO2014033077A1 (en)

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6024766B2 (en) 1978-03-23 1985-06-14 東洋醸造株式会社 sustained release antibiotic tablets
GB2176999B (en) 1985-06-22 1989-07-12 Stanley Stewart Davis Sustained release medicament
US5430037A (en) * 1988-11-25 1995-07-04 Henning Berlin Gmbh Chemie -Und Pharmawerk Oxypurinol alkali and alkalane earth salts in amorphous or crystalline form as agents for treating hyperuricaemia and gout
IT1246382B (en) 1990-04-17 1994-11-18 Eurand Int METHOD FOR THE TARGETED AND CONTROLLED DELIVERY OF DRUGS IN THE INTESTINE AND PARTICULARLY IN THE COLON
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
EP1023065A1 (en) * 1997-08-29 2000-08-02 Dsm N.V. Granules free of excipients
AU1337999A (en) * 1997-11-17 1999-06-07 Gist-Brocades B.V. Granules comprising clavulanate and one or more excipients
US6756057B2 (en) * 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
GB0031267D0 (en) 2000-12-21 2001-01-31 Smithkline Beecham Plc Novel compositions
US20040096496A1 (en) 2002-08-16 2004-05-20 Orchid Chemicals & Pharmaceuticals Limited Sustained release pharmaceutical composition of a cephalosporin antibiotic
EA011374B1 (en) * 2004-01-06 2009-02-27 Панацея Биотек Лимитед Non-disintegrating oral solid composition of high dose of water soluble drugs
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20060099253A1 (en) * 2004-10-20 2006-05-11 Wyeth Antibiotic product formulation
EP1861089A1 (en) * 2005-03-02 2007-12-05 KAIROSmed GmbH Oral modified release formulations containing 8-prenylnaringenin for continuous estrogen support
EA200702221A1 (en) 2005-04-12 2008-04-28 Элан Фарма Интернэшнл Лимитед CONTROLLED SHIPPING COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS CONTAINING CEFALOSPORIN
JP2008540691A (en) 2005-05-16 2008-11-20 エラン・ファルマ・インターナショナル・リミテッド Nanoparticles and controlled release compositions comprising cephalosporin
WO2007059916A2 (en) 2005-11-23 2007-05-31 Sandoz Ag Pharmaceutical composition
DE102006007830A1 (en) * 2006-02-17 2007-08-30 Grünenthal GmbH Storage-stable oral dosage form of amoxicillin and clavulanic acid
WO2007106957A1 (en) 2006-03-21 2007-09-27 Laboratoires Smb S.A. Multiple units controlled-release floating dosage forms
US20090111788A1 (en) * 2006-03-24 2009-04-30 Rajesh Jain Antibiotic compositions of modified release and process of production thereof
EP2061439A1 (en) 2006-09-12 2009-05-27 Glaxo Group Limited Pharmaceutical composition comprising a plurality of mini-tablets comprising a factor xa inhibitor
WO2008095263A1 (en) * 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
US20120027855A1 (en) 2007-07-06 2012-02-02 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
EP3714878B1 (en) 2007-07-06 2022-01-19 Lupin Limited Pharmaceutical compositions of rifaximin
US20120003312A1 (en) 2010-06-30 2012-01-05 Aptapharma, Inc. Multilayer Minitablets with Different Release Rates

Also Published As

Publication number Publication date
EP2890366A1 (en) 2015-07-08
CN104582692A (en) 2015-04-29
US20150238425A1 (en) 2015-08-27
WO2014033077A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
IL231203A (en) Selective and reversible inhibitors of ubiquitin specific protease 7, pharmaceutical compositions thereof and their therapeutic applications
HK1225390A1 (en) Boronates as arginase inhibitors and compositions and uses thereof
IL232113A (en) Boron-containing compounds, pharmaceutical compositions comprising them and uses thereof in inhibiting arginase
MX338515B (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors.
IL232038A (en) Oxalyl containing neprilysin inhibitors, process for their preparation and pharmaceutical compositions comprising them
IN2015DN03795A (en)
PL2938362T3 (en) Dry granulation process for producing tablet compositions of metformin and compositions thereof
MX2014011825A (en) Isoxazole î²-lactamase inhibitors.
EP2542514A4 (en) Fertilizer composition containing micronutrients and methods of making same
IL237321A0 (en) Ddr2 inhibitors and pharmaceutical compositions containing them
HRP20182155T1 (en) Pharmaceutical composition containing a mixture of proenzymes and enzymes
MX353061B (en) Novel low concentration meloxicam tablets.
IL222771A (en) Manufacture of active-free granules and tablets comprising the same
HK1216845A1 (en) Composition containing digestive enzymes and nutrients suitable for enteral administration
EP2626071A4 (en) Applications of arctigenin in formulating medicines for preventing or treating diseases related to red blood cell reduction
IL237322A0 (en) Solid pharmaceutical compositions containing levothyroxine and their preparation
TR201009167A2 (en) Pharmaceutical granules containing cephalosporin.
EP2576536A4 (en) Haematopoietic-prostaglandin d2 synthase inhibitors
MX2013013079A (en) Compositions comprising antibacterial agent and tazobactam.
IN2013MU02911A (en)
RS20130034A1 (en) Pharmaceutical mixture for the prolonged release of trimetazidine
IN2015DN01093A (en)
GEP201706675B (en) Imidazo-triazine derivatives as pde10 inhibitors
WO2012007758A3 (en) Pharmaceutical formulations
TR201103625A1 (en) Tablet formulation production process containing cefuroxime.